TNFRSF8 positive

This case underscores the importance of maintaining a high index of suspicion and performing thorough histopathological and immunohistochemical evaluation of all excised lesions, even when clinical features suggest a benign process. The rarity of this synchronous presentation underscores the need for heightened diagnostic vigilance and contributes valuable insight to the existing literature on unusual tumor associations in the oral and maxillofacial region.

There was no significant difference between the cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide regimen and the cyclophosphamide, vincristine, doxorubicin and prednisone regimen, whereas combinations with chidamide showed a trend toward an improved PFS. Within the cohort, 2 patients with relapsed and refractory CD30-positive PTCL-NOS received salvage chemotherapy with brentuximab vedotin (BV), a monoclonal antibody, and achieved complete metabolic remission, followed by sequential allogeneic haematopoietic stem-cell transplantation, resulting in long-term sustained remission. In conclusion, patients diagnosed with PTCL-NOS generally have a poor prognosis. Nevertheless, the use of innovative targeted therapies, such as chidamide and BV, shows potential to improve treatment outcomes in these patients.

Furthermore, the addition of eliglustat also enhanced the tumor-killing activity of brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate, both in vitro and in vivo. This glycoimmunotherapy paradigm represents a clinically actionable approach to overcome glycan-mediated immune evasion and enhance therapeutic efficacy in CD30-positive lymphomas.

Brentuximab vedotin-based regimens have reshaped frontline therapy for CD30-positive disease, while ongoing studies are exploring the role of novel therapies including epigenetic modulators, phosphatidylinositol 3-kinase (PI3K) and JAK inhibitors, and immune-based therapies across the PTCL spectrum. Future progress will depend on biomarker-driven clinical trials, refined patient selection, and the incorporation of genomic and immune signatures to personalize therapy.

Early biopsy, immunophenotypic analysis, and clinicopathologic correlation are essential to guide appropriate management in atypical or treatment-resistant lesions. Rather than demonstrating a novel association with HS, this report emphasizes diagnostic and classification challenges at the interface between primary cutaneous and systemic ALCL, which are of direct relevance to cutaneous pathologists.

Localized radiotherapy was then administered, which resulted in progressive improvement of the lesion from the first sessions, with tumor volume reduction, decreased exudate, and partial re-epithelialization of the ulcerated bed. This case highlights the role of localized radiotherapy as an effective palliative and disease-controlling modality for cutaneous CD30+ T-cell lymphoma, particularly in symptomatic or treatment-refractory lesions.

Complete clinical response was achieved with no recurrence at 18 months follow-up. This case highlights combined gemcitabine and radiotherapy as an effective alternative in selected high-risk pcALCL patients, demonstrating durable disease control.

Understanding the subtypes and molecular characteristics of ALCL is essential for optimizing therapeutic strategies. Therefore, this review summarizes recent research advances on ALK +/- ALCL to provide insights for optimizing treatment approaches.

This case demonstrates that IVLBCL can present with diffuse interstitial lung disease and generalized lymphadenopathy, expanding its recognized phenotypic spectrum. It may represent a variant with CD30-mediated nodal homing and immune activation.

Pediatric PCLs show heterogeneous behavior and therapeutic responses. Early biopsy of atypical or treatment-refractory eruptions, comprehensive histopathology and immunophenotyping, targeted EBV testing when suggested, and appropriate use of skin-directed radiotherapy (EBRT/TSEBT) and transplantation in selected refractory disease are essential. Multidisciplinary management and equitable access to specialized therapies are critical to optimize outcomes.

An 85-year-old male presented with multiple rapidly progressive, painful, ulcerative lesions, initially misdiagnosed as PG and treated with oral cyclosporine with no clinical response... The case documents an exceptionally rare cutaneous presentation of A-DLBCL, expanding the extremely limited literature on this enigmatic entity. Furthermore, it underscores the fundamental role of early skin biopsy in the differential diagnosis of non-specific ulcerative lesions, which is critical for ensuring appropriate treatment administration within the therapeutic window in cases of malignancy.